In December 2025, the FDA approved the Wegovy pill form, providing an oral semaglutide option for those avoiding injections
CERTAIN CONDITIONS MAY INDUCE A PREVIOUSLY UNKNOWN CONDITION OR UNDETECTED EPILEPTIC SYMPTOM IN USERS WHO HAVE SHOWN NO HISTORY OF ANY PRIOR SEIZURE OR EPILEPSY
Heat shock transcription factor 1 as a therapeutic target in neurodegenerative diseases
Lack of approval reflects insufficient human clinical trial data and incomplete evaluation of risks, dosing, and long-term effects
First-line antibiotic treatment includes ciprofloxacin 500mg twice daily for 7-14 days, or trimethoprim-sulfamethoxazole for uncomplicated cases in areas with low resistance rates
The rest of this article digs into what these drugs actually change in the body the cardiovascular benefits, the metabolic rewiring, the early signals in dementia and cancer, and what the next generation of multi-agonist peptides will look like